Implications of flavonoids as potential modulators of cancer neovascularity
Purpose The formation of new blood vessels from previous ones, angiogenesis, is critical in
tissue repair, expansion or remodeling in physiological processes and in various …
tissue repair, expansion or remodeling in physiological processes and in various …
Vascular endothelial growth factor receptors [VEGFR] as target in breast cancer treatment: current status in preclinical and clinical studies and future directions
M Malekan, MA Ebrahimzadeh - Current Topics in Medicinal …, 2022 - ingentaconnect.com
Breast cancer [BC] is one of the most common cancers among women, one of the leading
causes of a considerable number of cancer-related death globally. Among all procedures …
causes of a considerable number of cancer-related death globally. Among all procedures …
[HTML][HTML] Curcumol repressed cell proliferation and angiogenesis via SP1/mir-125b-5p/VEGFA axis in non-small cell lung cancer
C Ma, X Tang, Q Tang, S Wang, J Zhang… - Frontiers in …, 2022 - frontiersin.org
NSCLC (non-small cell lung cancer) is one of the most common and lethal malignant
tumors, with low 5-year overall survival rate. Curcumol showed antitumor activity in several …
tumors, with low 5-year overall survival rate. Curcumol showed antitumor activity in several …
[HTML][HTML] Dopamine D1 receptor in cancer
P Sobczuk, M Łomiak, A Cudnoch-Jędrzejewska - Cancers, 2020 - mdpi.com
Simple Summary Circulating hormones and their specific receptors play a significant role in
the development and progression of various cancers. This review aimed to summarize …
the development and progression of various cancers. This review aimed to summarize …
Response to BRAF-targeted therapy is enhanced by cotargeting VEGFRs or WNT/β-catenin signaling in BRAF-mutant colorectal cancer models
KB Tran, S Kolekar, Q Wang, JH Shih… - Molecular Cancer …, 2022 - AACR
The fact that 10% of colorectal cancer tumors harbor BRAF V600E mutations suggested
targeting BRAF as a potential therapy. However, BRAF inhibitors have only limited single …
targeting BRAF as a potential therapy. However, BRAF inhibitors have only limited single …
[HTML][HTML] Downregulation of Keap1 contributes to poor prognosis and Axitinib resistance of renal cell carcinoma via upregulation of Nrf2 expression
H Huang, Y Wu, W Fu, X Wang… - International …, 2019 - spandidos-publications.com
Kelch‑like ECH‑associated protein 1 (Keap1)/nuclear factor erythroid 2‑related factor 2
(Nrf2) signaling has a protective effect on normal cells. A number of previous studies …
(Nrf2) signaling has a protective effect on normal cells. A number of previous studies …
N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1DR activation
H Su, Z Xue, Y Feng, Y Xie, B Deng, Y Yao… - Toxicology and Applied …, 2019 - Elsevier
Previous studies showed that dopamine (DA) significantly reduces the frequency of cancer
stem-like cells (CSC) and enhances the efficacy of sunitinib (SUN) in the treatment of breast …
stem-like cells (CSC) and enhances the efficacy of sunitinib (SUN) in the treatment of breast …
[HTML][HTML] Constructing a novel prognostic model for triple-negative breast cancer based on genes associated with vasculogenic mimicry
Y Ren, L Feng, Z Tan, F Zhou, S Liu - Aging (Albany NY), 2024 - ncbi.nlm.nih.gov
Background: Research has shown a connection between vasculogenic mimicry (VM) and
cancer progression. However, the functions of genes related to VM in the emergence and …
cancer progression. However, the functions of genes related to VM in the emergence and …
[HTML][HTML] Physiologically-based pharmacokinetic/pharmacodynamic model of MBQ-167 to predict tumor growth inhibition in mice
J Reig-López, MM Maldonado, M Merino-Sanjuan… - Pharmaceutics, 2020 - mdpi.com
MBQ-167 is a dual inhibitor of the Rho GTPases Rac and Cdc42 that has shown promising
results as an anti-cancer therapeutic at the preclinical stage. This drug has been tested in …
results as an anti-cancer therapeutic at the preclinical stage. This drug has been tested in …
Preclinical PK/PD model for the combinatorial use of dexamethasone and sulpiride in the treatment of breast cancer
Q Yao, J Li, R Chen, Y Yao, J Xue, W Chen… - Acta Pharmacologica …, 2019 - nature.com
Previous studies show that dopamine D2-like receptor (D2DR) antagonist sulpiride (SUL)
enhances the antitumor efficacy of dexamethasone (DEX) in drug-resistant breast cancer …
enhances the antitumor efficacy of dexamethasone (DEX) in drug-resistant breast cancer …